Pfizer, BioNtech say flu-COVID shot generates strong immune response in trial
Pfizer (PFE.N) and German partner BioNTech said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against strains of the viruses in an early- to mid-stage trial. The companies said they plan to start a late-stage trial in the coming months....